Exploring A 110% Potential Upside In Biotechnology
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is drawing attention in the biotechnology sector with its promising clinical-stage oncology therapies and a compelling potential upside of 110.40%. As a company headquartered in Jerusalem, Israel, Alpha Tau focuses on the innovative field of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid tumors. With a market capitalization of $343.57 million, this biotech firm is making waves with its cutting-edge research and promising clinical trials.
**Current Valuation and Market Performance**
The current trading price for Alpha Tau stands at $4.04, showing a slight decrease of 0.04% recently. Over the past year, the stock has traded between $2.20 and $4.51, indicating…
